GlassScriptPhysician profile
Susan M Bordonaro
NPI 1366547358
$4,003.51
in general payments reported to CMS, 2019-2025
21 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $211 · 2023: $821 · 2024: $1,025 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,408 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.95 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $799.50 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $617.72 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $276.33 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $275.69 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $271.29 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $247.33 | 2023-2024 | Zoryve |
| Amgen INC. | $234.62 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $224.49 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $195.84 | 2024-2025 | Nemluvio, Aklief, Dysport |
| Regeneron Healthcare Solutions, INC. | $147.18 | 2024-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $146.60 | 2021-2024 | Jublia |
| Genzyme Corporation | $129.37 | 2021-2025 | |
| Blueprint Medicines Corporation | $114.22 | 2025 | |
| Pfizer INC. | $100.29 | 2021-2022 | |
| Revance Therapeutics, INC. | $63.66 | 2024 | Daxxify |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.94 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Organon LLC | $25.82 | 2025 | Vtama |
| Fresenius Kabi USA, LLC | $19.84 | 2025 | Adalimumab-Aacf |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $18.51 | 2025 | |
| Botanix Sb INC | $17.70 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bordonaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.